|
ALETZKI C, BOCK S, FRUH P: "NSG mice as hosts for oncological precision medicine", LAB INVEST., vol. 100, no. 1, 2020, pages 27 - 37, XP036966475, DOI: 10.1038/s41374-019-0298-6
|
|
ALTSCHUL SFGERTZ MEAGARWALA RSCHAFFER AAYU Y-K., NUCLEIC ACIDS, vol. 37, no. 3, 2009, pages 815 - 824
|
|
ALTSCHUL, S FGISH WMILLER WMYERS EWLIPMAN DJ.: "Basic Local Alignment Search Tool.", J. MOL. BIOL., vol. 215, 1990, pages 403 - 10, XP002949123, DOI: 10.1006/jmbi.1990.9999
|
|
ANDREATTA MALVAREZ BNIELSEN M., NUCLEIC ACIDS RES., vol. 45, no. 1, 2017, pages 458 - 463
|
|
ANN ONCOL., 2015
|
|
BEAR ASBLANCHARD TCESARE J ET AL.: "Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting", NAT COMMUN., vol. 12, no. 1, 16 July 2021 (2021-07-16), pages 4365, XP093018154, DOI: 10.1038/s41467-021-24562-2
|
|
BENDER R.R.MUTH A.SCHNEIDER I.C.FRIEDEL T.HARTMANN J.PLÜCKTHUN A.MAISNER A.BUCHHOLZ C.J.: "Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment", PLOS PATHOG., vol. 12, 2016, pages 1005641
|
|
BIJKER MSVAN DEN EEDEN SJFFRANKEN KLMELIEF CJMOFFRINGA RVAN DER BURG SH: "CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity", J IMMUNOL, vol. 179, no. 8, 2007, pages 5033 - 5040, XP055798792, DOI: 10.4049/jimmunol.179.8.5033
|
|
BOS RSHERMAN LA: "CD4+ T cell help in the tumour milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes", CANCER RES, vol. 70, 2010, pages 8368 - 8377
|
|
BOULTER JMGLICK MTODOROV PTBASTON ESAMI MRIZKALLAH PJAKOBSEN BK: "Stable, soluble T-cell receptor molecules for crystallization and therapeutics", PROTEIN ENG, vol. 16, 2003, pages 707 - 711, XP055479030, DOI: 10.1093/protein/gzg087
|
|
BREDA LPAPP T. E.TRIEBWASSER M. P.YADEGARI A.FEDORKY M. T.TANAKA N.ABDULMALIK O.PAVANI G.WANG Y.PARHIZ H.: "In vivo hematopoietic stem cell modification by mRNA delivery", SCIENCE, vol. 381, 2023, pages 436 - 443, XP093166089, DOI: 10.1126/science.ade6967
|
|
CASSIOLI CBALDARI CT: "The Expanding Arsenal of Cytotoxic T Cells", FRONT IMMUNOL., vol. 13, 2022, pages 883010
|
|
CHOI JGOULDING SCONN BMCGANN CDIETZE JKOHLER JLENKALA DBOUDOT AROTHENBERG DJURCOTT PSROUJI J, REPORTS METHODS, 2021, pages 100084
|
|
COHEN, S. N.CHANG ACYHSU L.: "onchromosomal antibiotic resistance in bacteria: Genetic transformation of Escherichia coli by R-factor DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 69, 1972, pages 2110 - 2114
|
|
COOMBE DRNAKHOUL AMSTEVENSON SMPERONI SESANDERSON CJ: "Expressed luciferase viability assay (ELVA) for the measurement of cell growth and viability", J IMMUNOL METHODS., vol. 215, no. 1-2, 1998, pages 145 - 150, XP004146501, DOI: 10.1016/S0022-1759(98)00081-7
|
|
COOPER L.J.N.TOPP M.S.PINZON C.PLAVEC I.JENSEN M.C.RIDDELL S.R.GREENBERG P.D: "Enhanced transgene expression in quiescent and activated human CD8+ T cells", HUM. GENE THER., 2004, pages 15648 - 658
|
|
DALLOUL A.: "CD5: a safeguard against autoimmunity and shield for cancers", AUTOIMMUN REV., vol. 8, no. 4, 2009, pages 349 - 53, XP025942099, DOI: 10.1016/j.autrev.2008.11.007
|
|
DUCREUX MCUHNA ASCARAMELLA C ET AL.: "Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", ANN ONCOL., vol. 28, 1 July 2017 (2017-07-01), pages 167 - 168
|
|
GIUNTOLI II RL, LU J, KOBAYASHI H, KENNEDY R AND CELIS E.: "Direct costimulation of tumour-reactive CTL by Helper T cells potentiate their proliferation, survival and effector function.", CLIN CANCER RES, vol. 8, 2002, pages 922 - 931
|
|
GUTIERREZ-GUERRERO AFRANGOIS-LOIC COSSETELS VERHOEYEN: "Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy", VIRUSES, vol. 12, no. 9, 2020, pages 1016, XP055946387, DOI: 10.3390/v12091016
|
|
HAN AGLANVILLE JHANSMANN LDAVIS MM: "Linking T cell receptor sequence to functional phenotype at the single cell level", NAT. BIOTECH., vol. 32, no. 7, 2014, pages 684 - 92, XP055309747, DOI: 10.1038/nbt.2938
|
|
HOBBS GAGUNAWARDENA HPBAKER RCAMPBELL SL: "Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function", SMALL GTPASES, vol. 4, no. 3, 2013, pages 186 - 192
|
|
HU YPETRONI GROLSON WCCZARKOWSKI ASMOLKIN MEGROSH WWCHIANESE-BULLOCK KASLINGLUFF CL: "Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine", CANCER IMMUNOL IMMUNOTHER, vol. 63, 2014, pages 779 - 786
|
|
ITO MHIRAMATSU HKOBAYASHI K ET AL.: "NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells", BLOOD, vol. 100, no. 9, 2002, pages 3175 - 3182
|
|
J. B. LIPPINCOTT COMPANY: "Pharmaceutics and Pharmacy Practice", 1982, J. B. LIPPINCOTT COMPANY, pages: 238 - 250
|
|
JOGLEKAR AV, SANDOVAL S.: "Pseudotyped Lentiviral Vectors: One vector, many guises.", HUM GENE THER METHODS, vol. 28, 2017, pages 291 - 301, XP055890845, DOI: 10.1089/hgtb.2017.084
|
|
JONES S.PENG P.D.YANG S.HSU C.COHEN C.J.ZHAO Y.ABAD J.ZHENG Z.ROSENBERG S.A.MORGAN R.A.: "Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes", HUM. GENE THER., 2009, pages 20630 - 640
|
|
JOSEPH A.ZHENG J.H.FOLLENZI A.DILORENZO T.SANGO K.HYMAN J.CHEN K.PIECHOCKA-TROCHA A.BRANDER C.HOOIJBERG E.: "Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1 )-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity", J. VIROL., 2008, pages 823078 - 3089
|
|
KARLIN SALTSCHUL, S.F.: "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes", PROC NATL ACAD SCI U S A., vol. 87, no. 6, March 1990 (1990-03-01), pages 2264 - 2268, XP001030853, DOI: 10.1073/pnas.87.6.2264
|
|
LANIGAN TMRASMUSSEN SMWEBER DP ET AL.: "Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyte® imaging system", J BIOL METHODS., vol. 7, no. 2, 2020, pages 133
|
|
LEIDNER RSILVA NSHUANG HSPROTT DZHENG CSHIH Y-PLEUNG APAYNE RSUTCLIFFE KCRAMER J, ENGL 1 MED, vol. 386, 2022, pages 2112 - 2119
|
|
MELSSEN MSLINGLUFF CL, CURR OPIN IMMUNOL., vol. 47, August 2017 (2017-08-01), pages 85 - 92
|
|
MURANSKI PANTONY PARESTIFO NPALLISON JP: "Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts", J. EXP. MED, vol. 207, 2010, pages 637 - 650
|
|
NELDE ARAMMENSEE HGWALTZ JS: "The peptide vaccine of the future", MOL CELL PROTEOMICS, vol. 20, 2021, pages 100022, XP093036984, DOI: 10.1074/mcp.R120.002309
|
|
PARAYATH NNSTEPHAN SBKOEHNE ALNELSON PSSTEPHAN MT: "In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo", NAT COMMUN., 2020, Retrieved from the Internet <URL:https://doi.org/10.1038/s41467-020-19486-2>
|
|
POOLE PKARUPPIAH VHARTT AHAIDAR JMOUREAU SDOBRZYCKI THAYES CROW- LEY CDIAS JHARPER H, NATURE COMMUN, vol. 13, 2022, pages 5333
|
|
PRIOR I.A., LEWIS P.D., MATTOS C.: "A comprehensive survey of ras mutations in cancer.", CANCER RES., vol. 72, 2012, pages 2457 - 2467, XP055117242, DOI: 10.1158/0008-5472.CAN-11-2612
|
|
QUEZADA SA, SIMPSON TR, PEGGS KS, MERGHOUB T, VIDER J, FAN X, BLASBERG R, YAGITA H,RAMMENSEE, H., BACHMANN, J., EMMERICH, N. P., B: "SYFPEITHI: database for MHC ligands and peptide motifs.", IMMUNOGENETICS, vol. 50, 1999, pages 213 - 219
|
|
RAWLA PSUNKARA TGADUPUTI V: "Epidemiology of pancreatic cancer: Global trends, etiology and risk factors", WORLD J ONCOL., vol. 10, no. 1, 2019, pages 10 - 27
|
|
ROBINSON RAMCMURRAN CMCCULLY MLCOLE DK: "Engineering soluble T cell receptors for therapy", THE FEBS JOURNAL, vol. 288, 2021, pages 6159 - 6173
|
|
SAIKI RK, GELFAND DH, STOFFEL S, SCHARF SJ, HIGUCHI, HORN GT, MULLIS KB, ERLICH HA.: "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.", SCIENCE, vol. 239, no. 4839, 1988, pages 487 - 91, XP001328036
|
|
SIEBART JCCHAN CSYAO XSU F-YKWONG GA.: "In vivo gene delivery to immune cells", CURR. OP. IN BIOTECH., vol. 88, August 2024 (2024-08-01), pages 103169
|
|
SPITZER MHCARMI YRETICKER-FLYNN NEKWEK SSMADHIREDDY DMARTINS MMGHERARDINI PFPRESTWOOD TRCHABON JBENDALL SC, CELL, vol. 168, 2017, pages 487 - 502
|
|
TILSEDA CMSADIQ BAPAPP TEAREESAWANGKIT PKIMURA KNOGUERA-ORTEGA ESCHOLLER JCERDA NAGHAJANIAN HBOT A: "IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation", PNAS, vol. 121, no. 13, 2024
|
|
TOMBÁCZ I.LACZKÓ DSHAHNAWAZ, MURAMATSU HNATESAN AYADEGARI APAPP TEALAMEH M-GSHUVAEV VMUI BLTAM YK: "Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs", MOL. THER. J. AM. SOC. GENE THER., vol. 29, 2021, pages 3293 - 3304, XP055933699, DOI: 10.1016/j.ymthe.2021.06.004
|
|
TRISSEL LA.: "ASHP Handbook on Injectable Drugs", 1986, pages: 622 - 630
|
|
TSUJI T.YASUKAWA M.MATSUZAKI J.OHKURI T.CHAMOTO K.WAKITA D.AZUMA T.NIIYA H.MIYOSHI H.KUZUSHIMA K.: "Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes", BLOOD, 2005, pages 106470 - 476
|
|
VAVASSORI VFERRARI SBERETTA SASPERTI CALBANO LANNONI AGADDONI, CVARESI ASOLDI MCUOMO A: "Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells", BLOOD, vol. 142, no. 9, 2023, pages 812 - 826, XP087387685, DOI: 10.1182/blood.2022019333
|
|
WADA T.: "Downregulation of CD5 and dysregulated CD8+ T cell activation", PEDIATR INT., vol. 60, no. 9, 2018, pages 776 - 780
|
|
WANG QJYU ZGRIFFITH KHANADA KRESTIFO NPYANG JC: "Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors", CANCER IMMUNOL RES., vol. 4, no. 3, 2016, pages 204 - 214, XP055314168, DOI: 10.1158/2326-6066.CIR-15-0188
|
|
WEBER EW, MAUS MV, MACKALL CL.: "The Emerging Landscape of Immune Cell Therapies.", CELL, vol. 181, 2020, pages 46 - 62
|
|
ZWAVELING SMOTA SCFNOUTA JJOHNSON MLIPFORD GBOFFRINGA RVAN DER BURG SJMELIEF CJM: "Established human papillomavirus type 16-expressing tumours are effectively eradicated following vaccination with long peptides", J. IMMUNOL, vol. 169, 2002, pages 350 - 358
|